Benzinga | Feb 12, 2021 06:10AM EST

JP Morgan Downgrades Amicus Therapeutics to Neutral, Announces $19 Price Target

JP Morgan analyst Anupam Rama downgrades Amicus Therapeutics (NASDAQ:FOLD) from Overweight to Neutral and announces $19 price target.